Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open Label, Phase II Study to Assess the Changes in Pigmentation and Safety of Subcutaneous, Bioresorbable Afamelanotide Implants in the Treatment of Vitiligo on the Face

NCT05210582 is registered in ClinicalTrials.gov with Clinuvel, Inc. as lead sponsor.

NCT NCT05210582
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05210582 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open Label, Phase II Study to Assess the Changes in Pigmentation and Safety of Subcutaneous, Bioresorbable Afamelanotide Implants in the Treatment of Vitiligo on the Face
Lead sponsor
Clinuvel, Inc.
Phase
Phase 2
Overall status
Unknown status
Start date
October 11, 2022
Completion date
August 31, 2023
Enrollment
6 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

vitiligo